Archil Jaliashvili: How Patients and Care Partners Navigate Chronic Illness and Transplant Medicine
Archil Jaliashvili, Co-owner, General Manager of SkinAI, Co-Chief Executive Officer at GeoBio Pharm, shared Jeff P.’s post on LinkedIn, adding:
”Jeff P. is a U.S.-based healthcare advocate and the Founder and President of the Cold Ischemia Foundation, focused on transforming how patients and care partners navigate chronic illness and transplant medicine.
He is not a ‘theoretical’ advocate, his own life 3 times kidney transplant, years in dialysis he definitely know what really needs:
- Less awareness campaigns
- More actionable frameworks and decision tools
- Less storytelling
- More operational guidance for real situations
- Innovation oriented to patient, outcomes
Core focus areas
- Organ transplantation and donation systems
- Chronic illness navigation
- Care partner support (often overlooked but critical)
His approach
Jeff P. is pushing a shift from traditional advocacy to structured, usable support systems.
Most healthcare systems assume patients and families will somehow coordinate care, make decisions, and manage complexity – often with zero preparation.
His work challenges that assumption directly by building infrastructure around the patient, not just messaging around the problem.”
Jeff P., Co-Founder at Cold Ischemia Foundation, shared a post on LinkedIn:
”Most advocacy talks. We build.
As Co-Founder of the Cold Ischemia Foundation, I have lived what most organizations only reference in reports. Decades inside a system that too often reduces people to data points forces a different perspective. You stop accepting surface-level solutions. You start demanding structure, accountability, and change that can actually be used in the real world.
Our work is not symbolic. It is operational.
The unique value of the Cold Ischemia Foundation is simple to state and difficult to replicate. We translate lived experience into tools, frameworks, and guidance that people can act on immediately. Not theory. Not awareness campaigns. Real resources designed for patients and care partners navigating chronic illness under pressure.
Care partners are expected to function as coordinators, advocates, and decision-makers with little preparation and no support. That is not just a gap. It is a systemic failure. We address it directly by building structured guides that help people survive, not just participate, in the care process.
While organ transplant and donation remain central to our mission, the reality is broader. Chronic illness does not exist in silos. The breakdowns we expose, fragmented communication, delayed decisions, lack of accountability, exist across conditions. Ignoring that connection is part of the problem. We are building a model that reflects the full landscape patients and families actually live in.
This is where advocacy changes.
Traditional advocacy raises awareness. We create clarity. We identify where systems fail, define those failures in practical terms, and provide pathways to navigate them. That shift matters because awareness without structure does not protect anyone.
There is also a level of seriousness here that cannot be overstated. When systems fail in healthcare, the consequences are not abstract. They are measured in lost time, deteriorating health, and preventable outcomes. Treating advocacy as messaging instead of infrastructure is no longer acceptable.
What we are building is not incremental. It is a restructuring of how advocacy functions. A model where patients and care partners are not passive voices, but informed, equipped participants with access to tools that match the complexity of the system they are forced to navigate.
This work is grounded in reality because it comes from it. And if done correctly, it has the potential to redefine what advocacy looks like across the entire healthcare landscape.
This is not about being heard.
It is about changing what happens next. Check out our page.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 16:39Yuriy Prokopenko: Advancing Hemostasis Through Scientific Collaboration
-
Aug 14, 2026, 16:26Antonio Paul: The Best Transfusion Is the One That Isn’t Needed
-
Aug 14, 2026, 16:24Thirunavukkarasu Angappan: What mRNA Manufacturing Teaches Us About Scaling Hemophilia Gene Therapy
-
Aug 14, 2026, 16:16Priyanka Raheja: Advancing Multidisciplinary Care for Women with Bleeding Disorders
-
Aug 14, 2026, 16:09Cristina Chang: Hemophilia B Gene Therapy BBM-H901 Approved in Macao
-
Aug 14, 2026, 16:03Muhammad Shaheer Bin Faheem: The Growing Mortality Divide in Thromboembolism and Hypertension
-
Aug 14, 2026, 15:53Peter Jaworski: Plasma Donation Myths and Why Plasma Matters
-
Aug 14, 2026, 15:50John Strouse: Why Older Adults with Sickle Cell Disease Should Be Included in Clinical Trials
-
Aug 14, 2026, 15:44Scott Cameron: Understanding Sex Differences in Platelet Biology